This manuscript has been assigned to a volume and issue but has not yet been published. It is either being edited, typeset or is in the proof stage of publication.
In the pre-published stage, this manuscript may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in this manuscript will be made at the time of publication and will be reflected in the final electronic version of the issue. The editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.
Prevalence of hypertension is high in the Caribbean while control of hypertension is low. Intervention trials are needed to establish low cost, sustainable approaches that work in this region.
Hypertension is an important risk factor for cardiovascular disease in the Caribbean and globally. It is responsible for 51% of deaths due to cerebrovascular disease (stroke) and 45% of deaths due to ischaemic heart disease, which are the leading causes of death in the Caribbean. The prevalence of hypertension in the Caribbean is high, affecting 21% of adults in Barbados and Trinidad and Tobago, 25% in Jamaica, and 35–38% in St Kitts, British Virgin Islands and Grenada, contributing to the large economic burden from this condition and its complications.
In developing countries, the risk of pulmonary tuberculosis (TB) in patients with HIV is two to six times that of persons without HIV infection (10, 11). The mortality among persons with HIV and TB is high. Even with the availability of ART, the risk of TB is reduced by ART in persons with HIV but is still not restored to a level comparable to persons without HIV infection.